GlassScriptPhysician profile
Peter V Mogyordy
NPI 1043203078
$8,447.08
in general payments reported to CMS, 2019-2025
17 companies · $680 in 2025
The $680 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $955 · 2021: $1,072 · 2022: $2,322 · 2023: $1,532 · 2024: $810 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126 · Entertainment: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.02 |
| Entertainment | $896.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,939.29 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $2,449.61 | 2021-2025 | Total30, Precision 1, Precision7 |
| Optos, INC. | $1,303.99 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $482.90 | 2019-2021 | |
| Lkc Technologies, INC. | $287.13 | 2023-2025 | |
| Abb Con-Cise Optical Group LLC | $255.11 | 2019-2021 | |
| Ivantis, INC | $142.86 | 2021 | |
| Bausch & Lomb Americas INC. | $128.23 | 2022-2024 | Infuse |
| Topcon Healthcare, INC. | $108.81 | 2023 | |
| Visioneering Technologies, INC. | $90.00 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $84.22 | 2019 | |
| Optovue, INC. | $47.50 | 2020 | |
| Visionix USA, INC | $36.17 | 2022 | |
| Sun Pharmaceutical Industries INC. | $29.50 | 2021 | |
| Dompe US, INC. | $26.06 | 2024 | Oxervate |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $21.64 | 2024 | Xdemvy |
| Maculogix, INC. | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mogyordy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.